The relationship between early biochemical failure and perineural invasion in pathological T2 prostate cancer

被引:34
作者
Endrizzi, J [1 ]
Seay, T
机构
[1] Wilford Hall USAF Med Ctr, Dept Urol, San Antonio, TX 78236 USA
[2] Brooke Army Med Ctr, Dept Urol, San Antonio, TX USA
关键词
prostate cancer; perineural invasion; prognosis; PSA; recurrence; management;
D O I
10.1046/j.1464-410x.2000.00518.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives To evaluate, in patients with pathologically localized prostate cancer, the relationship between early biochemical failure, i.e. an increasing prostate-specific antigen (PSA) level, and perineural invasion (PNI) on final pathology. Patients and methods The records were reviewed of 171 patients with prostate cancer who underwent prostatectomy atone institution between January 1992 and December 1995. Data on the histology, therapy and PSA level were collected and evaluated. Results Of the 171 patients with pathologically localized (pT2) prostate cancer, 131 were evaluable; 17 (13%) had a detectable PSA level in the first 5 years after surgery and 63 had PNI in the pathological specimen. Of those with PSA recurrence, 24 had PNI, one had no PNI and in two there was no comment on PNI. In comparison, only 10 of the 17 patients with recurrence had a Gleason sum of greater than or equal to 7. Conclusion Perineural invasion seems to be an important predictor of early outcome in patients with organ-confined prostate cancer treated by prostatectomy. In this series it was the most sensitive predictor of biochemical failure. A more detailed pathological evaluation of prostate cancer may allow the clinician to provide closer surveillance and better informed clinical decision-making.
引用
收藏
页码:696 / 698
页数:3
相关论文
共 12 条
[1]   RELATIONSHIP BETWEEN PERINEURAL TUMOR INVASION ON NEEDLE-BIOPSY AND RADICAL PROSTATECTOMY CAPSULAR PENETRATION IN CLINICAL STAGE-B ADENOCARCINOMA OF THE PROSTATE [J].
BASTACKY, SI ;
WALSH, PC ;
EPSTEIN, JI .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1993, 17 (04) :336-341
[2]  
Bonin SR, 1997, CANCER-AM CANCER SOC, V79, P75, DOI 10.1002/(SICI)1097-0142(19970101)79:1<75::AID-CNCR11>3.0.CO
[3]  
2-3
[4]  
BYAR DP, 1972, CANCER-AM CANCER SOC, V30, P5, DOI 10.1002/1097-0142(197207)30:1<5::AID-CNCR2820300103>3.0.CO
[5]  
2-S
[6]  
DESCHRYVERKECSKEMETI K, 1987, ARCH PATHOL LAB MED, V111, P833
[7]   Disease progression following radical prostatectomy in men with Gleason score 7 tumor [J].
Epstein, JI ;
Pound, CR ;
Partin, AW ;
Walsh, PC .
JOURNAL OF UROLOGY, 1998, 160 (01) :97-100
[8]   Nerve growth factor stimulates in vitro invasive capacity of DU145 human prostatic cancer cells [J].
Geldof, AA ;
DeKleijn, MAT ;
Rao, BR ;
Newling, DWW .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1997, 123 (02) :107-112
[9]  
GLEASON DONALD F., 1966, CANCER CHEMO THERAP REP, V50, P125
[10]   EXPRESSION OF A TRK HIGH-AFFINITY NERVE GROWTH-FACTOR RECEPTOR IN THE HUMAN PROSTATE [J].
PFLUG, BR ;
DIONNE, C ;
KAPLAN, DR ;
LYNCH, J ;
DJAKIEW, D .
ENDOCRINOLOGY, 1995, 136 (01) :262-268